US$ 28.66
glp-1 prescriptions growth slowdown 2024 Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP1 agonists set to become
Description
Our law firm is currently investigating cases on behalf of individuals who: Received Ozempic/Wegovy/Rybelsus/Trulicity/Mounjaro/Zepbound Brand Name (no generics or compounds) Received an actual diagnosis of nonarterial anterior ischemic optic neuropathy (NAION) while taking the drug Experienced some degree of permanent vision impairment Do you qualify for possible compensation

CrossRef Special Population Janus P

Timing gets weird
Verchere, Torben Hansen, Fredrik Karpe, Jens J

Do not discontinue GLP-1 medication without medical advice if you experience skin changes
